NCT04589663View on ClinicalTrials.gov

Study to Compare the Pharmacokinetics of Mometasone Furoate Alone and in Combination With Indacaterol in Patients ≥ 6 to < 12 Years Old With Asthma

PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

June 7, 2021

Primary Completion Date

April 11, 2022

Study Completion Date

April 11, 2022

Conditions
Asthma
Interventions
DRUG

Mometasone furoate

Single inhaled dose of 100 µg mometasone furoate (MF) administered via Twisthaler® on Day 1

DRUG

QMF149

Single inhaled dose of QMF149 (75/40 µg indacaterol acetate/MF fixed dose combination) administered via Concept 1 device on Day 6-9

DRUG

Standard of Care (Soc)

Asthma therapy: budesonide and salbutamol being the most frequently used (excluding MF and indacaterol acetate)

Trial Locations (3)

6529

Novartis Investigative Site, George

7531

Novartis Investigative Site, Cape Town

8800

Novartis Investigative Site, Nagykanizsa

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY